Study design.
We have performed a case/control study conducted between July 2015 and April 2016. The rules of Good Clinical Practices in Research and the ethical guidelines of the 1975 Declaration of Helsinki (1983 Revision) have been fully respected. Informed consent was obtained from all the patients, selected from the database of the Hemophilia Unit of the Region of Murcia with severe HA diagnosis and who were in treatment prophylactic with recombinant FVIII at the time of the study. The inclusion and exclusion criteria can be consulted in the supplementary document. Control subjects were obtained from healthy coworkers and doctors who voluntarily agreed to participate.
Sixteen patients with severe HA were included in the study. Although this may be considered as a low sample, these were all the patients available in our area at the time of the study. It is important to remember that HA is a rare disease.